fbpx

This MS drug switch means fewer relapses in study

This MS drug switch means fewer relapses in studyPublished: 30 November 2022 People with multiple sclerosis (MS) who switched from Gilenya (fingolimod) experienced fewer relapses than those who changed to Tysabri (natalizumab) or Mavenclad (cladribine) in a new study. The research included data from 1,045 patients from 26 countries. Each
Read More

This MS treatment causes frequent skin issues

This MS treatment causes frequent skin issues Published: 28 July 2021 Skin reactions are common in people with multiple sclerosis (MS) who are being treated with oral Mavenclad (cladribine) a new real-world study from Germany has found.  Almost a third (32%) of people studied developed some form of skin reaction
Read More